| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8416696 | Journal of Immunological Methods | 2018 | 9 Pages |
Abstract
The spiked sera and patient samples showed complement blockage with CH50, AH50 and C5 function assays when ECU >100â¯Î¼g/mL. CH50, AH50 or C5 function assays can serve as indicators for the pharmacodynamic effects of eculizumab. Allied to ECU concentration, laboratory studies may be helpful to tailor therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Maria A.V. Willrich, Bruna D. Andreguetto, Meera Sridharan, Fernando C. Fervenza, Linda J. Tostrud, Paula M. Ladwig, Ann M. Rivard, MeLea D. Hetrick, Ryan N. Olson, Sandra C. Bryant, Melissa R. Snyder, David L. Murray,